Biogen, AbbVie Withdraw Struggling MS Drug Zinbryta Due To Safety Issues
Executive Summary
Antibody was approved in the US with a liver safety warning while EU regulators recently limited the drug's use. Now, EMA has begun an urgent review of reports of inflammatory brain disorders related to Zinbryta.
You may also be interested in...
EMA Restricts Sanofi's Lemtrada Use, Initiates Risk-Benefit Review
Labeling changes for the multiple sclerosis drug being mandated by European regulators were made to the US label in January.
Biogen Moves Into Neuropsychiatry With Pfizer AMPA Receptor Modulator
The Phase IIb-ready, glutamate-modulating candidate shelved by Pfizer after a portfolio review will help Biogen offset the risk posed by its Phase III Alzheimer's candidate aducanumab.
EMA Calls For Zinbryta's ‘Immediate’ Suspension After More Reports of Brain Disorders
Biogen/AbbVie’s Zinbryta is already being withdrawn worldwide, but EMA now wants the MS drug recalled after mounting reports of serious brain disorders.